In the United States, the Multidisciplinary Association for Psychedelic Studies' (MAPS) investigation into MDMA-assisted psychotherapy for PTSD is currently on a fast track with the FDA, and physician prescribed psychedelic psychotherapy may be just a year or two away. The results from the MDMA-assisted psychotherapy trials show clear improvements in symptoms of the disorder. After living with treatment-resistant depression for nearly two decades, 70% of those treated no longer meet criteria for PTSD. The scientific study of psychedelic medicines like LSD, psilocybin mushrooms, MDMA, ayahuasca, DMT, mescaline/peyote, ketamine, and cannabis is very promising. Research investigating the transformational benefits of these compounds reveals that altered states of consciousness enhance creativity, and foster psychological, spiritual, and psychophysical healing.
